Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BEVERLY, Mass. and TORONTO, May 01, 2017 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne will present at the 2017 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 2, 2016 at 11:30 am Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in Canadian healthcare companies. Attendees will have an opportunity to obtain corporate updates from presenting companies and participate in 1-on-1 meetings with company management.
Mr. Wolf will be available for one-on-one meetings with the investment community on May 1st and 2nd. Investors attending the conference who wish to meet with Mr. Wolf should contact Hamilton Thorne at [email protected].
About the Conference
Bloom Burton & Co. is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. They aim to showcase approximately sixty of the premier Canadian healthcare companies to our network of investors, who generally join them from across Canada, the U.S. and Europe. There will be networking sessions, keynote speeches and panel discussions with venture capital, public equity and strategic investors. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in our 1-on-1 meeting system with company management.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics. Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact: David Wolf, President & CEO Hamilton Thorne Ltd. 978-921-2050 [email protected] Michael Bruns, CFO Hamilton Thorne Ltd. 978-921-2050 [email protected]
